Bristol Finds Biomarkers For Improved Response To Orencia In RA
This article was originally published in The Pink Sheet Daily
Executive Summary
Rheumatoid arthritis patients treated with Bristol’s Orencia who tested positive for two biomarkers of poor prognosis had a significantly greater response on outcomes than those who did not in a real-world data analysis presented at EULAR. The experience with TNF inhibitors was different.
You may also be interested in...
UroGen Approaches A Big Expansion In Bladder Cancer
The oncology company is preparing for the launch of UGN-102 for bladder cancer. CEO Liz Barrett talked to Scrip about the company’s next growth phase.
Cybin High On Psychedelic-Based CYB003 For MDD
The company will initiate a Phase III program in mid-2024, testing the deuterated psilocybin analog as an adjunctive treatment for depression on top of SSRIs.
Silence Open To A Partner But Ready To Go It Alone On Lp(a) Drug
The company said it has the financing to move forward with a Phase III program for zerlasiran in patients with high lipoprotein(a) at high risk of atherosclerotic cardiovascular disease.